RMD
ResMed Inc.247.34
-5.73-2.26%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
36.10BP/E (TTM)
25.32Basic EPS (TTM)
9.77Dividend Yield
0.01%Recent Filings
8-K
8-K
8-K
New board election and retirement
ResMed elected Nicole Mowad-Nassar, AbbVie's senior vice president overseeing a $6 billion portfolio across 17 therapeutic areas, to its board on August 15, 2025, effective immediately; she joins the Compensation and Leadership Development Committee with her 30 years of expertise in commercial strategy and digital health innovation. Meanwhile, long-serving director Rich Sulpizio announced his retirement effective November 19, 2025, after two decades of contributions, including chairing key committees. This shift bolsters ResMed's governance with fresh pharmaceutical insights. Mowad-Nassar adds sharp commercial depth.
10-K
FY2025 results
ResMed Inc. reports strong FY2025 results with net revenue of $5.1 billion, up 10% from $4.7 billion in FY2024, driven by 10% growth in both Sleep and Breathing Health and Residential Care Software segments. Gross margin expanded to 59.4% from 56.7%, reflecting operational efficiencies and reduced field safety notification expenses. Net income rose 37% to $1.4 billion, with diluted EPS increasing to $9.51 from $6.92, aided by a lower effective tax rate of 16.5% due to IRS refunds and business cessation benefits. Operating cash flow surged to $1.8 billion from $1.4 billion, supporting $300 million in share repurchases and $311 million in dividends. The company ended FY2025 with $1.2 billion in cash, up from $238 million, after repaying debt and investing in growth. ResMed highlights 10% constant currency revenue growth, with Sleep and Breathing Health up 10% and Residential Care Software up 10%, positioning for continued innovation in digital health and respiratory care.
8-K
CCO resigns from ResMed RCS
ResMed's chief commercial officer for its residential care software business, Bobby Ghoshal, announced his resignation on July 28, 2025, effective August 1, 2025, to become COO at a software firm in a non-competitive sector. This departure highlights potential leadership flux in the RCS unit. No successor named yet.
AHCO
AdaptHealth Corp.
10.35+0.08
ELMD
Electromed, Inc.
29.88+0.28
INSP
Inspire Medical Systems, Inc.
115.51-3.75
IRMD
iRadimed Corporation
96.87-0.15
IRME
IR-Med Inc.
0.02-0.01
MASI
Masimo Corporation
134.52-2.88
RMSL
RemSleep Holdings, Inc.
0.00+0.00
SOLV
Solventum Corporation
80.59-1.30
VMD
Viemed Healthcare, Inc.
7.26-0.11
VVOS
Vivos Therapeutics, Inc.
2.02+0.00